Cytophagic histiocytic panniculitis Advocacy Hub | UniteRare

At a Glance

Live from database

Regulatory Watchboard

10 events

Mar 2026Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

Medical College of Wisconsin — PHASE2

TrialNOT YET RECRUITING

Feb 2026Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study

Sun Yat-sen University — PHASE1, PHASE2

TrialNOT YET RECRUITING

Sep 2025A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP

Danielle Wallace — PHASE2

TrialRECRUITING

Jun 2025A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1

Institute of Hematology & Blood Diseases Hospital, China — PHASE2

TrialNOT YET RECRUITING

May 2025Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma

Second Affiliated Hospital, School of Medicine, Zhejiang University — PHASE2

TrialRECRUITING

Apr 2025A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Merck Sharp & Dohme LLC — PHASE2

TrialRECRUITING

Feb 2025POLA-R-CHP in the First-line Treatment of Transformed DLBCL

Fudan University — PHASE2

TrialRECRUITING

Sep 2023An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

Hoffmann-La Roche — PHASE3

TrialACTIVE NOT RECRUITING

Jul 2023Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

The First Affiliated Hospital of Soochow University — PHASE2

TrialENROLLING BY INVITATION

Jul 2022A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

Merck Sharp & Dohme LLC — PHASE2

TrialACTIVE NOT RECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

Total programs

No financial assistance programs currently listed for Cytophagic histiocytic panniculitis.
Check the disease page for updates →

Clinical Trial Landscape

No active clinical trials currently recruiting for Cytophagic histiocytic panniculitis.
Search all trials →

Search clinical trials for Cytophagic histiocytic panniculitis →

Recent News & Research

No recent news articles indexed yet for Cytophagic histiocytic panniculitis.
Search PubMed for Cytophagic histiocytic panniculitis →

Browse all Cytophagic histiocytic panniculitis news →

Specialist Network

Top 6 by expertise

Jennifer Crombie, MD, M.D

Dana-Farber Cancer Institute

📍 BOSTON, MA

Score 82 trials

Nirav Shah, MD

Medical College of Wisconsin

Score 45 trials

Wentong Wang

The First Affiliated Hospital of Nanjing Medical University

Score 01 pub

Meihua Zhang

The First Affiliated Hospital of Nanjing Medical University

Score 01 pub

Zhonglan Su

The First Affiliated Hospital of Nanjing Medical University

Score 01 pub

Xixi Xiong

The First Affiliated Hospital of Nanjing Medical University

Score 01 pub

View all Cytophagic histiocytic panniculitis specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰